💼🌏 AstraZeneca is making waves in 2026 with a groundbreaking $15 billion investment plan in the Chinese mainland, announced during UK Prime Minister Keir Starmer’s high-profile visit this week. CEO Pascal Soriot told CGTN’s Guan Xin the move reflects 'unshakable confidence' in China’s rapidly evolving healthcare and life sciences sectors.
🔬 The pharmaceutical giant aims to deepen collaboration with local innovators, tapping into China’s booming biotech ecosystem. Soriot highlighted partnerships with Shanghai and Beijing research hubs as key drivers for developing next-gen treatments targeting chronic diseases and rare conditions.
🤝 The deal arrives as China further opens its $1.3 trillion healthcare market to overseas investors. Analysts say AstraZeneca’s play could inspire more global firms to join China’s 'dual circulation' strategy, blending domestic innovation with international expertise.
💡 Soriot also teased upcoming AI-driven drug discovery projects with Chinese tech partners, calling it 'the future of personalized medicine.' With sustainability goals on the agenda, the company plans carbon-neutral manufacturing sites in Jiangsu province by 2028.
